Centessa Pharmaceuticals (CNTA) Return on Capital Employed (2021 - 2026)
Centessa Pharmaceuticals (CNTA) reported Return on Capital Employed of 40.87% for Q1 2026, down 381.0% year-over-year from 14.54% in Q1 2025, and down 3.3% quarter-over-quarter from 39.56% in Q4 2025.
Centessa Pharmaceuticals (CNTA) Return on Capital Employed (2021 - 2026) Analysis & Trends
Centessa Pharmaceuticals (CNTA) has 6 years of Return on Capital Employed data on file, last reported at 40.87% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 40.87%, down 381.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 40.87% (down 381.0% YoY), and the FY2025 annual result was 35.25%, up 1373.0% from the prior year.
- Return on Capital Employed declined to 40.87% in Q1 2026 per CNTA's latest filing, from 39.56% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 33.02% in Q1 2022 and troughed at 52.72% in Q1 2023.
- A 5-year average of 44.59% and a median of 46.16% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed plunged 1970 bps in 2023, then surged 1692 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 50.12% in 2022, then fell by 4 bps to 52.0% in 2023, then rose by 28 bps to 37.56% in 2024, then declined by 5 bps to 39.56% in 2025, then dropped by 3 bps to 40.87% in 2026.
- Business Quant data shows CNTA's Return on Capital Employed at 40.87% in Q1 2026, 39.56% in Q4 2025, and 48.47% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Centessa Pharmaceuticals | 6.15 Bn | 6.15 Bn | - | -40.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -40.87% |
| Dec 31, 2025 | -39.56% |
| Sep 30, 2025 | -48.47% |
| Jun 30, 2025 | -42.98% |
| Mar 31, 2025 | -37.06% |
| Dec 31, 2024 | -37.56% |
| Sep 30, 2024 | -33.83% |
| Jun 30, 2024 | -46.16% |
| Mar 31, 2024 | -50.03% |
| Dec 31, 2023 | -52.00% |
| Sep 30, 2023 | -50.75% |
| Jun 30, 2023 | -51.17% |
| Mar 31, 2023 | -52.72% |
| Dec 31, 2022 | -50.12% |
| Sep 30, 2022 | -49.56% |
| Jun 30, 2022 | -42.13% |
| Mar 31, 2022 | -33.02% |
| Dec 31, 2021 | -62.74% |
| Sep 30, 2021 | -53.24% |